1. Introduction {#sec1-molecules-21-00100}
===============

Cantharidin **1** ([Chart 1](#molecules-21-00100-f006){ref-type="fig"}), isolated from *Mylabris caraganae* and various other insects, is a terpenoid and has a high vesicant potency \[[@B1-molecules-21-00100]\]. It is used to treat piles, warts, ulcers, and molluscum through topical application and is also used as an abortifacient and aphrodisiac \[[@B1-molecules-21-00100],[@B2-molecules-21-00100]\]. In clinical studies, it had significant activity against liver tumors and the KB cell line in tissue culture at low concentrations \[[@B3-molecules-21-00100],[@B4-molecules-21-00100]\]. The clinical application of cantharidin is limited by its cytotoxic properties \[[@B5-molecules-21-00100],[@B6-molecules-21-00100]\]. It is an inhibitor of the serine/threonine protein phosphatases, PP1 and PP2A, leading to multiple cellular effects such as DNA damage, cell cycle arrest, and apoptosis \[[@B7-molecules-21-00100],[@B8-molecules-21-00100],[@B9-molecules-21-00100],[@B10-molecules-21-00100]\]. Cantharidin induces apoptosis in many human cancer cells such as pancreatic carcinoma \[[@B9-molecules-21-00100]\], colon cancer \[[@B10-molecules-21-00100]\], lung cancer \[[@B11-molecules-21-00100]\], melanomas \[[@B12-molecules-21-00100]\], and bladder cancer \[[@B13-molecules-21-00100]\]. It also induces endoplasmic reticular (ER) stress and autophagic cell death \[[@B13-molecules-21-00100],[@B14-molecules-21-00100],[@B15-molecules-21-00100]\]. Recently, certain reports indicated that *N*-cantharidin derivatives have antitumor and antihepatoma properties \[[@B16-molecules-21-00100],[@B17-molecules-21-00100],[@B18-molecules-21-00100],[@B19-molecules-21-00100]\]. Some cantharidinimides showed tumor-inhibitory action in animals, and several cantharidinimides exhibited inhibitory effects against xanthine oxidase \[[@B20-molecules-21-00100]\]. A number of modified cantharidin analogues were synthesized and their anticancer activities against a wide range of human tumor cell lines were evaluated \[[@B21-molecules-21-00100],[@B22-molecules-21-00100],[@B23-molecules-21-00100],[@B24-molecules-21-00100],[@B25-molecules-21-00100],[@B26-molecules-21-00100],[@B27-molecules-21-00100]\].

![Structures of cantharidin (**1**), cantharidinimines (**2**, **3**), and cantharidin-sulfanilamides.](molecules-21-00100-g006){#molecules-21-00100-f006}

In our previous research, we synthesized many cantharidinimides by modification with alkyl, phenyl, pyridinyl, thiazolyl, and thiadiazolyl groups \[[@B28-molecules-21-00100],[@B29-molecules-21-00100],[@B30-molecules-21-00100]\]. Those compounds showed certain degrees of cytotoxic activities against HL-60 (human myeloid leukemia cells), Hep 3B and Hep G2 (human hepatocarcinoma cells), NUGC (human gastric carcinoma cells), and HONE-1 (human nasopharyngeal carcinoma cells). Cantharidinimides with better solubility showed greater cytotoxicity against human hepatoma cell lines. The cantharidinimides with an electron-withdrawing group (R~1~) on the aromatic ring (X) exhibited increased cytotoxicity to cancer cell lines. Then, we used this feature and synthesized different imines to study their cytotoxic effects \[[@B31-molecules-21-00100]\]. These results showed that cantharidinimine derivatives had greater cytotoxic effects than cantharidinimides. Especially, cantharidinimine derivative **2** ([Chart 1](#molecules-21-00100-f006){ref-type="fig"}), which has a sulfanyl group, exhibited a 50% inhibitory concentration (IC~50~) value of 6 µM against HL-60 cells as did cantharidin (IC~50~ value of 7.2 µM).

However, cantharidinimides and their analogues also display inhibition of the inducible nitric oxide (NO) synthase (iNOS) pathway, and they inhibited NO synthase activity by more than 90%. Thus, they might be advantageous for anticancer therapy \[[@B32-molecules-21-00100],[@B33-molecules-21-00100]\]. Because of this, we synthesized canthardin sulfanilamides ([Chart 1](#molecules-21-00100-f006){ref-type="fig"}) and tested their cytotoxic effects on human cancer cell lines (HL-60 and Hep3B), human breast carcinoma cells (MCF7), and human breast carcinoma cells (MDA-MB-231) since incidence rates occur rapidly and more widely among Asian peoples than in Westerners. Growth inhibition was evaluated using an MTT assay. In order to find new cantharidinimides and related imides containing the sulfonamide group, we synthesized sulfonamido-ethyldicarboximide derivatives (**10i**--**k**, **11l**--**n**, **12o**--**p**, and **16q**--**s**) and tested their cytotoxic activities.

2. Results and Discussion {#sec2-molecules-21-00100}
=========================

2.1. Chemistry {#sec2dot1-molecules-21-00100}
--------------

We prepared effective cantharidin sulfanilamides by heating the reactant cantharidin (**1**) and primary arylamines of sulfanilamide derivatives (**4a**--**h**) to *ca.* 200 °C with 3 mL of dry toluene and 1--2 mL of TEA in a high-pressure sealed tube (Buchi glasuster 0032) to provide compounds **5a**--**h** in good yields ([Scheme 1](#molecules-21-00100-f003){ref-type="scheme"}). The sulfonamide derivatives containing pyrimidine, pyrazine, hydrogen, thiazole, and oxazole were sulfadiazine, sulfamethazine, sulfisomidine, sulfamerazine, sulfaquinoxaline, sulfacarbamide, 2-thiazolyl-sulfanilamide, and sulfamethoxazole (**4a**--**h**). Yields varied 2%--62% and showed a trend compatible with the expected basicity, and the characters of the bulky quinoxaline and the more-basic carbamide groups influenced compounds **5d** (6% yield) and **5e** (2% yield). The results obtained with **5a**--**c** and **5f**--**h**, however, showed the same strong electron-withdrawing sulfonyl (SO~2~) group and aromatic amino (NH~2~) basicity, which were unknown but really influenced the product yields, and the characters of a long side chain with resonance and induction effects were considered spontaneously.

![Synthesis of cantharidin-sulfanilamides **5a**--**h**.](molecules-21-00100-g003){#molecules-21-00100-f003}

In order to find some new cantharidinimides, cantharidin was treated with ammonia and yielded cantharidinimide (**6**) which was reacted with dimethyl or monomethyl-activated aziridins. Thus, **6** and its imide derivatives (**7** and **8**) were reacted with *N,N'*-dimethylformamide (DMF) in a sealed tube under reflux for 3 h, after which it was cooled, and then activated aziridine (**9**) was added dropwise and refluxed for another 2 h to yield compounds **10i**--**k**, **11l**--**n**, and **12o**--**p** ([Scheme 2](#molecules-21-00100-f004){ref-type="scheme"}). In this study, the ring opening reaction of *N*-sulfonyl 2,2-dimethylaziridine by imide nucleophiles ([Figure 1](#molecules-21-00100-f001){ref-type="fig"}a,d,e), which attacked the unsubstituted carbon, was detected. However, the ring-opening reaction of *N*-acyl 2,2-dimethylaziridine by various nucleophiles in the absence of an acid was reported to proceed with a formal attack on the tertiary carbon of the aziridine ring (abnormal opening) \[[@B34-molecules-21-00100]\]. No products of a "normal opening" (in the S~N~2 sense) were observed when the R groups were phenyl or biphenyl ([Figure 1](#molecules-21-00100-f001){ref-type="fig"}). The small amount of normal opening yield (when R was phenyl) was possibly the result of a displacement in the inversional ground states. It was through the regioselectivity ring-opening reaction, and the strong preference for normal-opening sulfonyl activation (R group was tosyl) that simply reflected the steric hindrance of a nucleophilic attack on the tertiary aziridine carbon in the inversional ground state. A single electron transfer (SET) mechanism was proposed to account for this unexpected behavior \[[@B35-molecules-21-00100],[@B36-molecules-21-00100]\]. Therefore, we proposed that both normal and abnormal opening reactions of activated aziridines were slowed down compared to a reaction in the absence of the two methyl groups, the former clearly more so than the latter, and the white crystalline compounds **10i**--**k** were obtained ([Scheme 2](#molecules-21-00100-f004){ref-type="scheme"}). The same method was used with cantharidin analogue compounds to obtain products **11l**--**n** and **12o**--**p**.

![Synthesis of compounds **10i**--**k**, **11l**--**n**, and **12o**--**p**.](molecules-21-00100-g004){#molecules-21-00100-f004}

![Regioselectivity in nucleophilic ring opening of *N*-sulfony and *N*-acyl activated 2-methylaziridine.](molecules-21-00100-g001){#molecules-21-00100-f001}

Structures of products **10j** and **10i** followed from the ^1^H-NMR spectra of chromatographic fractions, and the main evidence for **A** included signals of cantharidinimide's CH~3~ (position 8 and 9), NCH~2~ (position 10), and OCH (position 4 and 7) protons at 1.22 (singlet), 3.51 (singlet), and 4.54 ppm (singlet), respectively ([Table 1](#molecules-21-00100-t001){ref-type="table"}, [Figure 2](#molecules-21-00100-f002){ref-type="fig"}). These signals indicated the same values of the protons on two kinds of methyl, OCH, and NCH~2~ groups of product **10i** which might have greater steric hindrance (compared to **10j**, [Figure 2](#molecules-21-00100-f002){ref-type="fig"}B) repulsion between the two pairs of methyl groups, and the conformation for **10i** might have the least electrostatic repulsion between the proton of nitrogen and the two oxygen atoms of cantharidinimide with their negative partial charge. A downfield shift of product **10j** relative to **10i** was observed for these protons. These shifts and coupling constants ([Table 1](#molecules-21-00100-t001){ref-type="table"}) became complicated for several possible reasons: the hydrogen bonding bridge enhanced the electron-withdrawing capacity of the sulfonyl group and shifted the signals downfield from the usual range, and the three methyl groups might have less steric hindrance to each other. Thus, the structure became the conformationally fixed type B ([Figure 2](#molecules-21-00100-f002){ref-type="fig"}).

molecules-21-00100-t001_Table 1

###### 

^1^H chemical shifts (*™*) of sulfonamide-cantharidinimides **10i** and **10j** (CDCl~3~, 500 MHz).

  Position   10i                              10j
  ---------- -------------------------------- -------------------------------------
  4, 7       4.54 (s)                         4.55 (s)
  5, 6       1.68--1.70 (m); 1.79--1.81 (m)   1.67-1.70 (m); 1.79--1.83 (m)
  8, 9       1.22 (s)                         1.21 (s)
  10         3.51 (s)                         3.38 (dd, 3.8, 3.8); 3.61--3.64 (m)
  11         \-                               3.52 (dd, 9.7, 9.7)
  12         5.77 (s)                         4.68 (d, 9)
  15, 19     7.72 (d, 8)                      7.70 (d, 8)
  16, 18     7.23 (d, 8)                      7.27 (d, 8)
  20         2.39 (s)                         2.41 (s)
  21         1.14 (s)                         0.93 (d, 6.7)
  22         1.14 (s)                         \-

![Conformation of **10i** and **10j**.](molecules-21-00100-g002){#molecules-21-00100-f002}

The *N*-pyrimidyl, *N*-thiazolyl, *N*-oxazolylsulfonylcantharidinimides, **5a**--**h**, were prepared by means of a pressure technique synthesis, and their analogous derivatives (**10i**--**k**, **11l**--**m**, and **12o**--**p**) were synthesized via nucleophilic ring opening of methyl- or dimethylbenzenesulfonylaziridine and methyl- or dimethyltoluenesulfonylaziridine, after reacting with several analogous nucleophilic bases. Compounds **16q**--**s** were obtained from *N*-hydroxylimide **13** and activated aziridine by treatment with NaH base in dry THF for 24 h ([Scheme 3](#molecules-21-00100-f005){ref-type="scheme"}). After evaporation, it was purified by silica gel column chromatography and recrystallized in methanol. From these reactions, it should be noted that the characters of various bases ([Figure 1](#molecules-21-00100-f001){ref-type="fig"}a--e) strongly confirmed the influence of the positions of the ring opening of the activated aziridines. The preparative technique, the temperature, the drying solvent, and the formation of nucleophilic bases were also influenced by other factors that can cause strong variations in the results. The reaction steps and time were also crucial factors in this formation. The results of these yields strongly confirmed the influence of the sulfanilamide side chain (**5e**, 2%, R = H).

![Synthesis of compounds **16q**--**s**.](molecules-21-00100-g005){#molecules-21-00100-f005}

2.2. Pharmacology {#sec2dot2-molecules-21-00100}
-----------------

Cytotoxicities of the cantharidin-sulfanilamide derivatives, **5a**--**h**, were tested by suppressing the growth of the HL-60, Hep3B, MCF7, and MDA-MB-231 human carcinoma cells using MTT cell viability assays. Some compounds showed inhibitory effects on HL-60 and Hep3B cells. Cantharidin **1** was more toxic and exhibited greater cytotoxicity, while the synthesized cantharidinimides were less toxic but also exhibited inhibitory effects ([Table 2](#molecules-21-00100-t002){ref-type="table"}). In this study, compound **5a**, which had two methyl groups on the pyrimidyl ring, displayed strong inhibitory effects on the HL-60 and Hep3B cell lines, as did cantharidin. *N*-Cantharidinimido-sulfamethazine **5a** was less toxic compared to *N*-cantharidinimino-sulfamethazine **2** against HL-60. This result confirmed our previous study. Compounds **5b** and **5c** also had methyl groups, but, unfortunately, no activities were detected against either of the two cell lines as compounds **5h** and **5d**, thus the methyl group positions highly influenced the results. Compound **5g** with an oxazolyl group exhibited medium cytotoxicity against the Hep3B cell line, but compound **5f**, although with a thiazolyl group, displayed no inhibitory effects on either cell line. Aziridine side chains contained imide derivatives, and analogues **10i**--**k**, **11l**--**n**, **12o**--**p**, and **16q**--**s** exhibited weak inhibitory effects against the Hep3B cell line but displayed very low effects against the HL-60, MCF7, and MDA-MB-231 cell lines.

molecules-21-00100-t002_Table 2

###### 

Cytotoxicity effect of **1**, cantharidin-sulfanilamides (**5a**--**h**), and imide analogues (**10i**--**k**, **11l**--**n**, **12o**--**p**, and **16q**--**s**) in human hepatocellular carcinoma (Hep3B), myeloid leukemia (HL-60), and human breast adenocarcinoma (MCF7 and MDA-MB-231) cell lines.

  Cpd No.   IC~50~ (μM) ^a^                   
  --------- ----------------- ------- ------- -------
  **1**     5.6               3.4     \-      \-
  **5a**    38.2              9       \>100   \>100
  **5b**    \>100             \>100   \>100   \>100
  **5c**    \>100             \>100   \>100   \>100
  **5d**    \>100             \>100   \>100   \>100
  **5e**    \>100             \>100   \>100   \>100
  **5f**    \>100             \>100   \>100   \>100
  **5g**    \>100             17      \>100   \>100
  **5h**    \>100             80      \>100   \>100
  **10i**   \>100             \>100   \>100   \>100
  **10j**   \>100             \>100   \>100   \>100
  **10k**   \>100             \>100   \>100   \>100
  **11l**   \>100             \>100   \>100   \>100
  **11m**   \>100             \>100   \>100   \>100
  **11n**   \>100             \>100   \>100   \>100
  **12o**   \>100             \>100   \>100   \>100
  **12p**   \>100             \>100   \>100   \>100
  **16q**   \>100             \>100   \>100   \>100
  **16r**   \>100             \>100   \>100   \>100
  **16s**   \>100             \>100   \>100   \>100

^a^ IC~50~ was calculated after 48 h of continuous drug exposure, values are the mean of three to four experiments with coefficients of variation of 5%--10%.

The cytotoxicity of cantharidin was investigated in both the NCI and Oncotest cell line panels \[[@B37-molecules-21-00100]\]. It showed profound activity at low micromolar concentrations (log~10~IC~50~ values of −6.980 to −5.009 M), and revealed extreme cytotoxicity toward cell lines of diverse tumor types. According to a COMPARE analysis \[[@B38-molecules-21-00100]\] of microarray-based transcriptome-wide mRNA expressions, 21 genes were found to be significantly correlated with the response of 60 tumor cell lines to cantharidin. Some researchers screened their synthetic compounds against human cancer cell lines and used a COMPARE analysis to evaluate the anticancer activity and predict the probable mechanism \[[@B27-molecules-21-00100],[@B39-molecules-21-00100],[@B40-molecules-21-00100],[@B41-molecules-21-00100],[@B42-molecules-21-00100]\]. Therefore, the following studies examined the possible mechanism using a standard NCI-60 test and COMPARE analysis of **5a**.

3. Experimental Section {#sec3-molecules-21-00100}
=======================

3.1 Synthesis {#sec3dot1-molecules-21-00100}
-------------

### 3.1.1. General Experimental Procedures {#sec3dot1dot1-molecules-21-00100}

General procedures were followed for the reaction of ammonia with cantharidine and the other acid anhydride. These compounds were prepared according to similar procedures, and the reactions took place in high-pressure tubes (Büchi Glasuster 0032, Zürich, Switzerland). Cantharidin or acid anhydrides were added to a tube containing 3 mL of dry toluene and triethylamine (TEA), and the solution was stirred and heated to *ca.* 200 °C. After being stirred for 2 h, the mixture was evaporated, and the residual mass was purified by column chromatography on silica gel and recrystallized from methanol.

All temperatures are reported in degrees centigrade. Melting points were determined with a Büchi B-545 melting point apparatus (Büchi, Flawil, Switzerland) and were uncorrected. $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{20}$ values were recorded on a JASCO P-1020 Digital Polarimeter (JASCO, Tokyo, Japan). Infrared spectra were recorded on a Perkin-Elmer Model 882 (Thermo Fisher Scientific Inc., New York, NY, USA) and Nicolet 510 pet and Thermo Mattson IR 300 (Thermo Fisher Scientific Inc.) spectrophotometers. ^1^H-nuclear magnetic resonance (NMR) spectra (in CDCl~3~ unless otherwise stated) were recorded at 500 MHz on a Bruker Advance DRX and AM-500 FT (Bruker Co., Bremen, Germany). Mass spectra were obtained on a JOEL JMSHX 110 FAB-MS (Joel, Tokyo, Japan) spectrometer and MAT-95XL HRMS (Finnigan, München, Germany).

### 3.1.2. Test Samples {#sec3dot1dot2-molecules-21-00100}

Chinese blister beetles were extracted with a water--ethanol (1:1) solution, filtered through celite, purified by chromatography on silica gel, and then recrystallized with ethanol to give cantharidin **1**. Compounds **5a**--**h**, **10i**--**k**, **11l**--**n**, **12o**--**p**, and **16q**--**s** were prepared from cantharidin, acid anhydride, and primary amines in the presence of TEA in toluene in high-pressure tubes. The mass spectra of all compounds were measured, and ^1^H-NMR was also used for testing.

### 3.1.3. Physical Data of Cantharidinimide Derivatives and Analogues {#sec3dot1dot3-molecules-21-00100}

*N-Cantharidinimido-sulfamethazine* (**5a**): 62% yield, m.p. 195--196 °C. IR (KBr): 1709 (amide) cm^−1^; ^1^H-NMR: δ 1.25 (6H, s), 1.75--1.77 (2H, m), 1.86--1.87 (2H, m), 2.05 (6H, s), 4.69 (2H, t, *J* = 2.3, 2.6 Hz), 6.64 (1H, s, pyrimidinyl H), 7.52 (2H, d, *J* = 8.6 Hz, phenyl H), 8.26 (2H, d, *J* = 8.7 Hz, phenyl H); FAB-MS *m/z* (rel. int.): 457 \[M + H\]^+^ (100), 154, 124; HRMS, calcd. for C~22~H~25~N~4~O~5~S \[M + H\]^+^ 457.1546, found 457.1547.

*N-Cantharidinimido-sulfisomidine* (**5b**): 49% yield, m.p. 163--164 °C. IR (KBr): 1710 (amide) cm^−1^; ^1^H-NMR: δ 1.26 (6H, s), 1.75--1.77 (2H, m), 1.78--1.80 (2H, m), 2.54 (3H, s), 2.67 (3H, s), 4.69 (2H, t, *J* = 2.3 Hz), 6.9 (1H, s, pyrimidinyl H), 7.55 (2H, d, *J* = 8.4 Hz, phenyl H), 8.06 (2H, d, *J* = 8.4 Hz, phenyl H); FAB-MS *m/z* (rel. int.) 457 \[M + H\]^+^ (22), 279, 154; HRMS (FAB^+^), calcd. for C~20~H~22~N~3~O~6~S 457.1546, found 457.1549.

*N-Cantharidinimido-sulfamerazine* (**5c**): 10% yield, m.p. 254--256 °C. IR (KBr): 1710 (amide) cm^−1^; ^1^H-NMR: δ 1.25 (6H, s), 1.74--1.76 (2H, m), 1.84--1.87 (2H, m), 2.42 (3H, s), 4.68 (2H, t, *J* = 2.3 Hz), 6.80 (1H, d, *J* = 5.2 Hz, pyrimidinyl H), 7.52 (2H, d, *J* = 8.5 Hz, phenyl H), 8.24 (2H, d, *J* = 8.6 Hz, phenyl H), 8.42 (1H, d, *J* = 5.1 Hz, pyrimidinyl H); HRMS (FAB^+^), calcd for C~21~H~23~N~4~O~5~S 443.1311, found 443.1313.

*N-Cantharidinimido-sulfaquinoxaline* (**5d**): 6% yield, m.p. 253--255 °C. IR (KBr):1704 (amide) cm^−1^; ^1^H-NMR: δ 1.20 (6H, s), 1.67--1.71 (2H, m), 1.80--1.84 (2H, m), 4.63 (2H, t, *J* = 2.8, 2.4 Hz), 7.45--7.48 (3H, m, H-6' peak overlap, *J* = 8.5 Hz), 7.58 (2H, t-like, 2H), 7.89 (1H, d, *J* = 8.2 Hz, H-8'), 8.14 (2H, d, *J* = 8.6 Hz), 8.59 (1H, s). HRMS (FAB^+^), calcd. for C~24~H~22~N~4~O~5~S 478.1305, found 478.1307.

*N-Cantharidinimido-sulfacarbamide* (**5e**): 2% yield, m.p. 115--116 °C. IR (KBr): 1776, 1706 (amide) cm^−1^; ^1^H-NMR (DMSO-*d*~6~): δ 1.28 (6H, s), 1.69--1.70 (2H, m), 1.95--1.96 (2H, m), 4.63 (2H, t-like), 7.54 (2H, d, *J* = 8.6 Hz), 8.02 (2H, d, *J* = 8.4 Hz); HRMS, calcd. for C~16~H~18~N~2~O~5~S 350.0894, found 350.0895.

*N-Cantharidinimido-N'-(2-thiazolyl)-sulfanilamide* (**5f**): 10% yield, m.p. 125--127 °C. IR (KBr): 1706 (amide) cm^−1^; ^1^H-NMR: δ 1.25 (6H, s), 1.74--1.76 (2H, m), 1.85-1.87 (2H, m), 4.68 (2H, s), 6.54 (1H, d, *J* = 4.5 Hz, thiazolyl N-CH), 7.12 (1H, d, *J* = 4.5 Hz, thiazolyl S-CH), 7.47 (2H, d, *J* = 8.2 Hz, phenyl H), 8.02 (2H, d, *J* = 8.5 Hz, phenyl H); FAB-MS m/z (rel, int): 434 \[M + H\]^+^ (50), 154 (100); HRMS, calcd. for C~19~H~20~N~3~O~5~S~2~ 434.0844, found 434.0847.

*N-Cantharidinimido-sulfamethoxazole* (**5g**): 35% yield; m.p. 211--213 °C. IR (KBr): 1710 (C=O) cm^−1^; ^1^H-NMR (acetone-*d*~6~): δ 1.58 (6H, s), 2.25--2.26 (4H, m), 5.02 (2H, t, *J* = 2.8 Hz), 2.78 (3H, s), 6.69 (1H, s), 8.01 (2H, t, *J* = 6.9 Hz), 8.48 (2H, d, *J* = 6.7, 1.9 Hz); FAB-MS *m/z* (rel, int): 432 \[M + H\]^+^ (100); HRMS calcd. for C~20~H~22~N~3~O~6~S 432.1229, found 432.1226.

*N-Cantharidinimido-sulfadiazine* (**5h**): 27% yield; 262--263 °C; IR (KBr): 1710 (amide) cm^−1^; ^1^H-NMR (acetone-*d*~6~): δ 1.27 (6H, s), 1.64--1.66 (4H, m), 4.57 (2H, t, *J* = 2.8 Hz), 7.06 (1H, t, *J* = 4.7 Hz), 7.54 (2H, t, *J* = 4.3 Hz), 8.23 (2H, t, *J* = 4.3 Hz), 8.50 (2H, d, *J* = 5.0 Hz); FAB-MS *m*/*z* (rel, int) 429 \[M + H\]^+^ (100); HRMS calcd. for C~20~H~21~N~4~O~5~S 429.1233, found 429.1229.

*N-(2,2-Dimethylethyl-p-toluolsulfonamide)cantharidinimide* (**10i**): 14% yield, 154--155 °C. IR (KBr): 1147 (S(=O)~2~), 1401 (S(=O)~2~), 1691 (C=O), 3264 (NH) cm^−1^; ^1^H-NMR (see [Table 1](#molecules-21-00100-t001){ref-type="table"}); HRMS, calcd. for C~21~H~28~N~2~O~5~S 420.1719, found 420.1718.

*N-(2-Methylethyl-p-toluolsulfonamide)cantharidinimide* (**10j**); 21% yield, m.p. 223--225 °C. IR (KBr): 1139 (S(=O)~2~), 1397 (S(=O)~2~), 1691 (C=O), 3244 (NH) cm^−1^; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{20}$ −5.6 (*c* 0.5, CHCl~3~); ^1^H-NMR (see [Table 1](#molecules-21-00100-t001){ref-type="table"}); HRMS, calcd. for C~20~H~26~N~2~O~5~S 406.1562, found 406.1560.

*N-(2,2-Dimethylethyl-benzosulfonamide)cantharidinimide* (**10k**): 22% yield, m.p. 155-156 °C. IR (KBr): 1152 (S(=O)~2~), 1400 (S(=O)~2~), 1695 (C=O), 3253 (NH) cm^−1^; ^1^H-NMR: δ 1.13 (6H, s), 1.23 (6H, s), 1.68--1.70 (2H, m), 1.78--1.81 (2H, m), 3.52 (2H, s), 4.53 (2H, t, *J* = 2.4 Hz), 5.88 (1H, s), 7.44 (2H, t, *J* = 7.4 Hz), 7.49 (1H, t, *J* = 7.3, 7.2 Hz), 7.84 (2H, d, *J* = 7.5 Hz); HRMS, calcd. for C~20~H~26~N~2~O~5~S 406.1562, found 406.1564.

*N-\[2,2-Dimethylethylamino\]-1-naphtharinimido-4-methylsulfanilamide* (**11l**): 10% yield, m.p. 247--248 °C (MeOH). IR (KBr): 1151 (S(=O)~2~), 1384 (S(=O)~2~), 1715 (C=O), 3284 cm^−1^; ^1^H-NMR (CDCl~3~, 500 Hz): δ 1.28 (6H, s), 2.30 (3H, s), 3.89 (2H, s), 5.69 (1H, s), 7.10 (2H, d, *J* = 8.1 Hz), 7.67 (2H, d, *J* = 8.2 Hz), 7.78 (2H, dt-like, *J* = 4.0, 7.0, 8.5 Hz), 7.88 (2H, dt-like, *J* = 3.1, 5.3, 6.8 Hz); HRMS (EI, 80 ev), calcd. C~19~H~20~N~2~O~4~S 372.1144, found 372.1143.

*N-\[2-Methylethylamino\]-1-naphtharinimido-4-methylsulfanilamide* (**11m**): 73% yield, m.p. 200--202 °C (MeOH). IR (KBr): 1135 (S(=O)~2~), 1397 (S(=O)~2~), 1711 (C=O), 3313 cm^−1^; ^1^H-NMR: *δ* 1.28 (3H, d, *J* = 6.4 Hz), 2.09 (3H, s), 3.52 (2H, dt-like, *J* = 4.5, 10.1, 14.4 Hz), 3.68 (1H, d, *J* = 7.6 Hz), 4.88 (1H, d, *J* = 7.9 Hz), 6.86 (2H, d, *J* = 8.0 Hz), 7.53 (2H, d, *J* = 8.1 Hz), 7.71 (4H, dt-like, *J* = 5.4, 9.0, 10.2 Hz); HRMS (EI, 80 ev), calcd. C~18~H~18~N~2~O~4~S 358.0987, found 358.0986.

*N-\[2,2-Dimethylethylamino\]-1-naphtharinimidosulfanilamide* (**11n**): 34% yield, m.p. 202--203 °C (MeOH). IR (KBr): 1155 (S(=O)~2~), 1392 (S(=O)~2~), 1715 (C=O), 3276 cm^−1^; ^1^H-NMR: δ 1.29 (6H, s), 3.67 (2H, s), 5.78 (1H, s), 7.31 (2H, t, *J* = 7.7 Hz), 7.39 (1H, t, *J* = 7.5 Hz), 7.76 (2H, qd, *J* = 7.5, 5.5, 3.1, 3.1 Hz), 7.81 (2H, dd-like *J* = 7.7, 1.1), 7.88 (2H, dd, *J* = 3.1, 5.4 Hz); HRMS (EI, 80 ev), calcd. C~18~H~18~N~2~O~4~S 358.0987, found 358.0989.

*N-\[3-(1,3-Dioxo-1,3,3a,4,7,7a-hexahydro-isoindol-2-yl)-2,2-dimethylethyl\]-4-methyl-benzenesulfonamide* (**12o**): 22% yield, m.p. 133--134 °C (MeOH). IR (KBr): 1143 (S(=O)~2~), 1397 (S(=O)~2~), 1707 (C=O), 3272 (NH) cm^−1^; ^1^H-NMR: δ 1.20 (6H, s), 2.22 (2H, dd, *J* = 4.2, 4.6 Hz), 2.40 (3H, s), 2.57 (2H, dd, *J* = 1.6, 1.6 Hz), 3.10 (2H, t, *J* = 2.8 Hz), 3.47 (2H, s), 5.79 (2H, t, *J* = 3.1Hz), 5.85 (1H, s), 7.25 (2H, d, *J* = 9.4 Hz), 7.71 (2H, d, *J* = 8.2 Hz); HRMS (EI, 80 ev), calcd. C~19~H~24~N~2~O~4~S 376.1457, found 376.1458.

*N-\[3-(1,3-Dioxo-1,3,3a,4,7,7a-hexahydro-isoindol-2-yl)-2-methylethyl\]-4-methyl-benzenesulfonamide* (**12p**): 22% yield, m.p. 145--146 °C (MeOH). IR (KBr): 1160 (S(=O)~2~), 1401 (S(=O)~2~), 1695 (C=O), 3280 (NH) cm^−1^; ^1^H-NMR: δ 1.00 (3H, d, *J* = 6.6 Hz), 2.23 (2H, dd, *J* = 5.3, 15.5 Hz), 2.41 (3H, s), 2.54 (2H, d, *J* = 18.1 Hz), 2.96 (1H, dd, *J* =2.7, 2.9 Hz), 3.01 (1H, dd, *J* = 2.7, 10.7 Hz), 3.31 (1H, dd, *J* = 3.7, 13.7 Hz), 3.49 (1H, dt-like, *J* = 5.9, 9.4, 10.9 Hz), 3.61 (1H, s), 4.78 (1H, d, *J* = 8.4 Hz), 5.88 (2H, t, *J* = 2.2 Hz), 7.28 (2H, d, *J* = 8.1 Hz), 7.70 (2H, d, *J* = 8.1 Hz); HRMS (EI, 80 ev), calcd. for C~18~H~22~N~2~O~4~S 362.1300, found 362.1298.

*exo-N-Hydroxyl-7-oxabicyclo\[2.2.1\]hept-5-ene-2-phenylsulfonamido-1-methylethyl-2,3-dicarboximide* (**16q**): 13% yield, m.p. 127--133 °C (MeOH). IR (KBr): 1709 (C=O) cm^−1^; ^1^H-NMR: δ 1.34 (3H, d, *J* = 3.3 Hz), 2.71 (2H, s), 2.99--3.03 (2H, m, N-CH~2~), 4.23--4.24 (1H, m, O-CH), 5.02 (1H, s), 5.19 (1H, s), 6.47 (2H, s), 7.49--7.55 (3H, m), 7.85--7.86 (2H, m); FAB-MS *m/z* (rel. int. %): 379 \[M + H\]^+^ (15), 311 (48), 270 (34), 70 (75), 56 (100).

*exo-N-Hydroxyl-7-oxabicyclo\[2.2.1\]hept-5-ene-2-phenylsulfonamido-2-methylethyl-2,3-dicarboximide* (**16r**): 9% yield; 174--176 °C (MeOH); IR (KBr): 1690 (C=O) 3327 cm^−1^; ^1^H-NMR: δ 1.23 (3H, d, *J* = 2.8 Hz), 2.74 (2H, dd, *J* = 5.4, 7.3 Hz), 3.88 (2H, td, *J* = 2.8, 4.2, 8.2 Hz), 3.51 (1H, dd, *J* = 3.1, 4.4 Hz), 5.24 (2H, d, *J* = 4.9 Hz), 6.50 (2H, s), 7.49 (3H, dt-like, *J* = 5.8, 6.0, 11.3 Hz), 7.84 (2H, dt-like, *J* = 5.4, 6.0, 9.9 Hz); FAB-MS *m/z* (rel. int. %): 379 \[M + H\]^+^ (3), 135 (70), 74 (75), 197 (35).

*exo-N-Hydroxyl-7-oxabicyclo\[2.2.1\]hept-5-ene-2-\[(2',5'-dichlorophenyl)sulfonamidoethyl\]-2,3-dicarboximide* (**16s**): 48% yield, m.p. 212-216 °C (MeOH). IR (KBr): 1780 cm^−1^; ^1^H-NMR: *δ* 2.77 (2H, s), 3.21 (2H, dd, *J* = 5.5, 10.1 Hz), 4.09 (2H, t, *J* = 9.5 Hz), 5.25 (2H, s), 6.50 (2H, s), 6.40 (1H, t, 11.9 Hz), 7.44 (2H, s), 8.04 (1H, s); FAB-MS *m/z* (rel. int. %): 433 \[M + H\]^+^ (4), 155 (30), 365 (10); HRMS (FAB^+^), calcd. for C~16~H~15~N~2~O~6~Cl~2~S 433.0029, found 433.0005.

3.2. Antineoplastic Bioassays {#sec3dot2-molecules-21-00100}
-----------------------------

### 3.2.1. Cell Culture {#sec3dot2dot1-molecules-21-00100}

Media and sera for cell culture were purchased from Gibco/BRL (Grand Island, NY, USA). Most chemicals were purchased from Sigma Chemical (St. Louis, MO, USA). The human hepatoma (Hep3B) and myeloid leukemia (HL-60) cell lines were obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA). The human breast cancer cell lines, MDA-MB-231 and MCF-7, were purchased from the cell bank of the National Health Research Institute (Miaoli, Taiwan). These cells were maintained as monolayers in Dulbecco's modified Eagle's medium (DMEM) containing 10% heat-inactivated fetal bovine serum (FBS), 100 units/mL penicillin, 100 μg/mL streptomycin, 100 μM nonessential amino acids, and 1 mM glutamine in a controlled atmosphere of 5% CO~2~ and 95% air at 37 °C.

### 3.2.2. MTT Assay for Cellular Viability {#sec3dot2dot2-molecules-21-00100}

Cells were seeded into 96-well plates and allowed to adhere for 24 h before drugs were introduced. Following a 48-h incubation, drugs and media were removed, and each well was treated with 100 μL of 500 μg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in culture medium. Following a 4-h incubation period to allow the metabolism of MTT by mitochondrial dehydrogenases of viable cells to form an insoluble formazan product, the plates were centrifuged at 450× *g* for 10 min, and supernatants were removed and replaced with 100 μL DMSO. The plates were shaken to maximize solubilization of the formazan crystals. The absorbance, as a measure of viable cell numbers, was read the following day in a model MA310 automated EIA plate reader (Whittaker M. A. Bioproducts, Inc., Walkersville, MD, USA) at a wavelength of 550 nm. IC~50~ values were obtained by a linear regression analysis of the percent absorbance *vs.* the log of the drug concentration. It was previously shown that viable cell numbers are correlated with the optical density as determined in the MTT assay.

4. Conclusions {#sec4-molecules-21-00100}
==============

We synthesized cantharidinimide derivatives, **5a**--**h**, and their analogues **10i**--**k**, **11l**--**n**, **12o**--**p**, and **16q**--**s**. The most potent cytostatic compound, *N*-cantharidinimido-sulfamethazine (**5a**), exhibited anti-HL-60 and anti-Hep3B cell activities. Two compounds, **5g** and **5h**, displayed slight effects on the Hep3B cell line, while the other compounds produced no response in these four cell lines. Although they exhibited very low effects on human carcinoma cells, we observed that these compounds contained sulfamoyl moieties. When studying the structure-activity relationship, we found that these compounds had very similar chemical structures to some diuretics, antidiabetic drugs, and hypoglycemic agents. Thus, their pharmacological effects should be tested in the future.
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